Cancer Check Labs

What Cancer Check Labs does

Cancer Check Labs LLC is a privately-held, Dallas-based clinical laboratory company that commercializes a single direct-to-consumer Multi-Cancer Early Detection (MCED) blood test branded "Cancer Check." The test uses Circulating Tumor Cell (CTC) capture technology to extract whole circulating tumor cells from a blood sample, then applies gold-standard histopathology methods — Hematoxylin and Eosin (H&E) staining and Immunohistochemistry (IHC) — followed by review and sign-off by a board-certified pathologist, with a pathology report issued for every result. The product screens for more than 200 types and sub-types of solid tumor cancers and claims Stage 0 detection capability, before tumors are visible on imaging.

The company operates under a CLIA-certified laboratory (regulated by CMS) and is HIPAA-compliant; the test is not FDA cleared or approved. The primary revenue mechanism is a one-time $1,995 per-test fee paid by US consumers via the company's e-commerce storefront, with international access via select physicians in Canada. Distribution is a hybrid of direct-to-consumer e-commerce and B2B channel partnerships spanning medical doctors, functional health practices, wellness/MedSpas, employer benefits programs, and a partner network of phlebotomy service providers. Notable commercial anchors include an exclusive partnership with Ways2Well and a $2.5 million test donation to Dallas-area firefighters via the Save a Firefighter nonprofit.

Cancer Check Labs was founded in 2010 by Sumit Rai (CEO/Chairman, ex-Mobclix founder) and Denny Cahan (President/COO, ex-SIS co-founder with a $65M exit), both personally motivated by family cancer losses. The company has not disclosed institutional venture or growth equity funding and is currently founder-financed. Recent operating activity (2024–2025) has focused on geographic expansion into new US states and Canada, channel-partner buildout, advisory board strengthening, and earned-media positioning rather than capital raises or M&A.

Name

Cancer Check Labs

Legal name

Cancer Check Labs LLC

Website

https://cancerchecklabs.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

51–100 employees

Short description

Cancer Check Labs operates a CLIA-certified Dallas laboratory that sells a $1,995 direct-to-consumer blood test using Circulating Tumor Cell capture and board-certified pathology review to screen for 200+ solid tumor cancers as early as Stage 0.

Ownership category

akta.pro rank

Product category

Cancer Diagnostics

NAICS

Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing (HLAAANAG)

akta.pro secondary industries

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Reference & Esoteric Testing Laboratories (HLAFAMAJ)

Keywords

• Multi-cancer early detection
• Circulating tumor cell analysis
• Cancer screening blood test
• Pathology diagnostic services
• Early cancer detection

Headquarters

HQ city

Dallas

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Cancer Check Test Sales (US): Direct-to-consumer sales of the Cancer Check multi-cancer early detection blood test in the United States at a fixed price of $1,995 per screening. The test includes a blood draw kit, phlebotomy services, laboratory analysis, and a board-certified pathology report.

Pricing tiers

Go-to-market motion2 records

Distribution channels6 records

Marketing channels9 records

Core offering

Cancer Check Labs sells the Cancer Check Multi-Cancer Early Detection (MCED) blood test, which captures whole circulating tumor cells (CTCs) from a single blood draw and uses H&E and IHC histology protocols reviewed by a board-certified pathologist. The test screens for more than 200 types and sub-types of solid tumor cancers, including as early as Stage 0, and is delivered as a direct-to-consumer kit at $1,995 with results returned via email in approximately two weeks. The product is available in the United States (excluding Hawaii and Alaska) and through select doctors in Canada.

Product overview

Cancer Check Labs offers a single unified product—the Cancer Check Multi-Cancer Early Detection (MCED) blood test. This test uses circulating tumor cell (CTC) detection technology to screen for over 200 types and sub-types of solid tumor cancers, detecting cancer as early as Stage 0. Every test result includes a board-certified pathology report, reviewed by a qualified medical doctor. The product is available for purchase in the United States at $1,995 per screening, with international availability via select doctors in Canada.

Differentiator

Problem solved

Functional benefit

Products and services

• Cancer Check A Multi-Cancer Early Detection (MCED) blood test that captures whole circulating tumor cells (CTCs) from a single blood draw and uses H&E and IHC histology, reviewed by a board-certified pathologist, to screen for more than 200 types and sub-types of solid tumor cancers as early as Stage 0. Each result is delivered with a physician-grade pathology report in approximately two weeks for $1,995 per screening in the US.

Quantifiable outcome

• 99% survival rate when cancer detected at Stage 0
• +2 more outcomes

Named customers2 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered major, flagship and core.

• Dr. Raj Attariwala (Scientific & Medical Advisory Board)majorStrategic or Co-development Partner · 30 April 2025Dr. Raj Attariwala, a renowned radiologist and nuclear medicine expert, joined Cancer Check Labs' Scientific & Medical Advisory Board. He is co-author of Oncorads (global standardized MRI technique for cancer screening) and emeritus founder/creator of Prenuvo scan. His expertise in PET/CT and whole-body MRI brings imaging integration capabilities to the company's early detection approach.
• Ways2WellflagshipStrategic or Co-development Partner · 14 August 2024Ways2Well selected Cancer Check Labs as its exclusive provider of early cancer detection tests. This exclusive partnership provides Ways2Well's patients access to Cancer Check's breakthrough multi-cancer early detection test with board-certified pathology reports.
• Evexia DiagnosticsmajorStrategic or Co-development Partner · 13 August 2024Evexia Diagnostics and Cancer Check Labs announced a partnership to make early, accurate cancer detection more widely available. The collaboration brings advanced, pathologist-reviewed early cancer detection to more providers and patients nationwide. The partnership aims to expand access to Cancer Check's MCED test through Evexia's network.
• Adopt a Firefighter / Save a FirefightermajorStrategic or Co-development Partner · 13 August 2024Save a Firefighter (formerly Adopt A Firefighter), a nonprofit providing firefighters with free cancer screening, launched with a $2.5 million donation of Cancer Check Labs tests to Dallas area firefighters. Firefighters face up to 3x higher cancer incidence than the general population, making early detection particularly valuable for this group.
• Phlebotomy Service PartnerscoreChannel Partner/ Reseller/ DistributorCancer Check partners with local phlebotomy services across the United States to enable convenient blood draws for customers. These partners are essential to the test delivery process, allowing customers to schedule blood draws at locations convenient to them after purchasing the test online.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Natera: Natera is a publicly traded molecular diagnostics company offering Signatera (MRD) and other cell-free DNA tests. While its core focus is MRD and reproductive testing, its cfDNA platform overlaps with Cancer Check's liquid biopsy category and competes for the same oncology clinical and consumer mindshare.
• Fountain Life: Fountain Life operates premium longevity and preventive health centers offering whole-body imaging and advanced biomarker screening to affluent members. It is a direct channel partner archetype for Cancer Check's employer and wellness/MedSpa distribution, and competes for the same executive health customer wallet.
• Prenuvo: Prenuvo offers whole-body MRI screening as a cash-pay preventive service for early cancer and disease detection. It serves a highly overlapping customer segment (affluent, health-conscious consumers, longevity clinics) with a complementary (imaging) modality, and is connected to Cancer Check via advisory board member Dr. Raj Attariwala, who founded Prenuvo's MRI technique.
• Function Health: Function Health is a consumer-facing preventive diagnostics platform offering comprehensive blood biomarker panels and early detection testing via membership. It targets the same health-conscious, self-pay consumer seeking proactive screening and overlaps with Cancer Check's individual consumer segment.

Direct peers

• GRAIL: GRAIL's Galleri test is the most prominent MCED blood test on the US market, using next-generation sequencing of ctDNA methylation patterns to detect a multi-cancer signal. Cancer Check and GRAIL sell the same conceptual product (single-blood-draw multi-cancer screening) to overlapping consumer and clinician segments, though they compete on underlying biology (CTC vs ctDNA) and on the inclusion of a board-certified pathology report.

Broad incumbents

• Thorne: Thorne is a large consumer health and supplements brand that has expanded into diagnostic testing and partnerships (e.g., with OneMedNet and telehealth platforms). While not a direct MCED competitor, it competes in the same functional/wellness retail channel and increasingly offers advanced at-home health tests.
• Tempus AI: Tempus AI is a technology-driven precision medicine company offering molecular profiling and AI-based diagnostics across oncology. While primarily B2B/clinician-facing, it represents the broader precision oncology and data-driven diagnostics ecosystem Cancer Check operates in and could expand into MCED over time.
• Guardant Health: Guardant Health offers liquid biopsy tests for therapy selection and recurrence monitoring (Guardant360, Reveal) and is developing Shield for multi-cancer screening. Its oncology liquid biopsy platform overlaps with Cancer Check's technology category, and Guardant has far larger commercial scale, payer relationships, and FDA-cleared products.
• Exact Sciences: Exact Sciences markets Cologuard (colorectal screening) and is developing an MCED test (Cancerguard) through large prospective trials. While focused on colorectal today, Exact Sciences is the largest publicly traded cancer diagnostics company and the most likely scaled competitor to enter Cancer Check's broader MCED space with deeper clinical evidence and reimbursement leverage.
• Roche (Foundation Medicine): Roche, through Foundation Medicine and its diagnostics division, offers comprehensive oncology molecular profiling (FoundationOne CDx, FoundationOne Liquid CDx) and has indicated interest in multi-cancer screening. As one of the largest global diagnostics incumbents, it represents the scale competitor Cancer Check would face if Roche expands its MCED footprint.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@CancerCheck
• Facebookfacebook.com/Cancerchecklabs
• LinkedInlinkedin.com/company/cancerchecklabs
• Instagraminstagram.com/cancerchecklabs
• Xx.com/cancerchecklabs

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cancer Check Labs